Krystal Biotech
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
Something off on this page? Send us feedback.
Profile
Commercializes VYJUVEK, a topical, redosable gene therapy for dystrophic epidermolysis bullosa, while advancing engineered HSV-1 treatments for eye, lung, skin, and tumor diseases. Revenue remains concentrated in VYJUVEK, and manufacturing is anchored by two in-house facilities.
Commercializes VYJUVEK, a topical, redosable gene therapy for dystrophic epidermolysis bullosa, across the United States, Europe, and Japan. The treatment is approved in the United States, European Union, United Kingdom, and Japan, with direct launches in major markets and specialty distributors elsewhere.
Builds engineered HSV-1 vectors for noninvasive or minimally invasive delivery across skin, eye, lung, and tumor tissue. Clinical programs include eye drops KB803 and KB801, inhaled KB407 and KB408, topical KB111, and oncology candidate KB707; Jeune Aesthetics develops injectable skin-aging program KB304. Development and commercial production are supported by two in-house manufacturing facilities.
Revenue remains concentrated in VYJUVEK, while European access depends on country-level pricing and reimbursement and every other program remains investigational.
Company facts
Key statistics
Year to date +42.3% · Average volume (30d) 458.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Initiate | Outperform | $400 | ||
| Jul 13, 2026 | Jefferies | Reiterate | Buy | $371 | $474 | |
| Jun 16, 2026 | H.C. Wainwright | Target | $310 | $361 | ||
| May 5, 2026 | Evercore ISI | Target | $206 | $300 | ||
| Feb 18, 2026 | Chardan Capital | Reiterate | Buy | $216 | $323 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | $1.70 | $1.79 | +5.3% | $120.9M | $119.2M | −1.4% | −8.37% |
| May 4, 2026Q1 FY26 | $1.45 | $1.83 | +26.2% | $112.1M | $116.4M | +3.8% | −0.83% |
| Feb 17, 2026Q4 FY25 | $1.62 | $1.70 | +4.9% | $105.3M | $107.1M | +1.7% | −1.58% |
| Nov 3, 2025Q3 FY25 | $1.12 | $2.66 | +137.5% | $105.3M | $97.8M | −7.1% | +2.73% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $88.2M | $96.0M | $97.8M | $107.1M | $116.4M | $119.2M | |
| Gross profit | $83.2M | $88.9M | $92.1M | $96.2M | $110.0M | $112.8M | |
| Operating income | $36.2M | $39.3M | $41.4M | $44.4M | $53.7M | $58.4M | |
| Net income | $35.7M | $38.3M | $79.4M | $51.4M | $55.9M | $54.8M | |
| Diluted EPS | $1.20 | $1.29 | $2.66 | $1.70 | $1.83 | $1.79 | |
| Gross margin | 94.3% | 92.5% | 94.2% | 89.8% | 94.6% | 94.6% | |
| Operating margin | 41.0% | 40.9% | 42.3% | 41.5% | 46.1% | 49.0% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $50.7M · FY24 $290.5M · FY25 $389.1M
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $845.6M · Total debt $8.9M · Total assets $1.50B · Shareholders' equity $1.36B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 29.48M · Float 23.51M · 79.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 4.42M | 14.99% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 4.18M | 14.18% | 13F | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 2.89M | 9.80% | 13F | Aug 14, 2026 |
| Krish S. Krishnan · director, 10 percent owner, officer: President and CEO | 2.88M | 9.76% | Form 4 | Jun 5, 2026 |
| Suma Krishnan · director, 10 percent owner, officer: President, R&D | 2.86M | 9.70% | Form 4 | Jun 5, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Dino A. Rossi | director | −25,000 | $329.12 |
| Jun 25, 2026 | John Charles Thomas | officer: EVP, General Counsel | −1,000 | $347.27 |
| Jun 4, 2026 | Krish S. Krishnan | director, 10 percent owner, officer: President and CEO | −25,000 | $308.12 |
| Jun 4, 2026 | Suma Krishnan | director, 10 percent owner, officer: President, R&D | −25,000 | $308.11 |
| May 26, 2026 | John Charles Thomas | officer: EVP, General Counsel | −642 | $302.03 |
Peers
- Abeona Therapeutics
Only FDA-approved DEB rival; autologous gene therapy vs VYJUVEK
- Vertex Pharmaceuticals
CF modulator franchise that defines the market KB407 must enter
- Arcturus Therapeutics
Direct KB407 rival: inhaled mRNA for Class I CF via LUNAR platform
- Beam Therapeutics
AATD base-editing challenger; BEAM-302 pivotal cohort planned H2 2026
- Wave Life Sciences
AATD RNA editing rival: WVE-006 Phase 1b/2a, first human RNA edit
- BridgeBio Pharma
10-K-named DEB rival via affiliate Phoenix Tissue Repair (PTR-01)
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Krystal Biotech | $351.46 | +0.05% | $10.36B | 44.0 | 41.3 | 23.5 | +24.1% |
| Abeona Therapeutics | $5.97 | +0.67% | $337.4M | — | — | 13.2 | +2,745.0% |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Arcturus Therapeutics | $15.10 | −0.59% | $431.7M | — | — | 18.1 | −87.9% |
| Beam Therapeutics | $29.32 | +0.10% | $3.02B | — | — | 19.3 | −94.2% |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Median | 31.5 | 27.8 | 16.7 | −30.7% |